ClinicalTrials.gg
Active, not recruitingNCT07537231Updated May 7, 2026

A Clinical Study to Evaluate the Absorption, Metabolism, and Excretion of Oral [14C]GS1-144 in Healthy Postmenopausal Female Participants

A Phase 1 interventional study of [14C]GS1-144 in Healthy Postmenopausal Women, Absorption and Metabolism, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Active, not recruiting at 1 site in China. Open to female participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-07.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Health services research

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
40 Years to 65 Years
Sex
Female
01

Study summary

This is a single-center, non-randomized, open-label, single-dose clinical PK study in healthy postmenopausal female participants.

Read the detailed description

This is a single-center, single-dose, open-label design study, planned to enroll 6-8 healthy postmenopausal female participants to evaluate the human mass balance of [14C]GS1-144. Each participant will receive a single oral dose of approximately 30 mg/100 µCi of [14C]GS1-144 oral formulation. During the study, blood, urine, and feces samples will be collected at specified time points/intervals. By measuring the the total radioactivity (TRA )concentration in whole blood and plasma, and the concentrations of GS1-144, its metabolite M1, and other metabolites (if applicable) in plasma, the PK parameters of TRA of [14C]GS1-144 in plasma and whole blood (if applicable) and the PK parameters of GS1-144, its metabolite M1, and other metabolites (if applicable) in plasma will be calculated, and the distribution of TRA between whole blood and plasma will be determined; by measuring the amount of radioactivity in urine and feces, the TRA recovery, radioactivity excretion data, and main excretion pathways will be obtained; through the analysis of the radioactive metabolite profile in plasma, urine, and feces and the structural identification of major metabolites, the metabolic and elimination pathways of GS1-144 in humans will be determined.

02

Conditions studied

  • Healthy Postmenopausal Women
  • Absorption
  • Metabolism
  • Excretion
03

In context

Lead sponsor

Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 112 studies on the registry; 48 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy female participants meeting the menopause criteria at screening visit: natural menopause (defined as continuous spontaneous amenorrhea ≥ 12 months) or continuous spontaneous amenorrhea ≥ 6 months with serum follicle-stimulating hormone (FSH) > 40 IU/L, or ≥ 6 weeks after bilateral oophorectomy for benign disease (with or without hysterectomy);
  2. Age at the time of signing the form (ICF): 40-65 years old (inclusive);
  3. (BMI) range of 19-27.9 kg/m2 (inclusive), and body weight not less than 45 kg;
  4. Fully understand the purpose and requirements of this study, and voluntarily sign the ICF;
  5. Able to communicate well with the study personnel and to complete the study in accordance with the protocol.

Exclusion criteria

Exclusion Criteria:

Auxiliary Examinations:

  1. abnormalities found during vital signs, physical examination, chest X-ray (posteroanterior view), ophthalmological examination, digital rectal examination, abdominal B-ultrasound, or gynecologic ultrasound;
  2. Abnormal laboratory tests at screening (hematology, blood chemistry, coagulation function, urinalysis, stool routine and occult blood, thyroid function, parathyroid function, sex hormones, see Appendix 2 for details) that are judged by the investigator to be clinically significant;
  3. Resting interval (corrected using Fridericia's formula, QTcF = QT/RR\^1/3) obtained from 12-lead > 460 ms for females; or other abnormalities judged by the investigator to be clinically significant;
  4. Clinically significant abnormal results for surface antigen (HBsAg), virus antibody IgG (Anti-HCV IgG), treponema pallidum antibody, or antibody as judged by the investigator;
  5. Abnormal serum pregnancy test results judged clinically significant by the investigator; participants with natural menopause, total hysterectomy, or bilateral oophorectomy may be exempted from pregnancy testing;

    Medication History:

  6. Use of any prescription drugs within 4 weeks prior to first dose [including but not limited to any drugs that alter liver enzyme activity (e.g., , sex hormones, anticonvulsants, cyclosporine, etc.)], or use of any over-the-counter drugs (including but not limited to Chinese herbal medicines, Chinese herbal compound preparations, health products, etc.) and vitamin supplements within 2 weeks prior to first dose; including use of cytochrome P450 1A2 (CYP1A2) inducers within 3 months prior to administration of the product, or use of CYP1A2 inhibitors within 2 weeks or 5 half-lives (whichever is longer) prior to administration (see Appendix 1 for details);

    Medical and Surgical History:

  7. History of syncope with hypotension, orthostatic hypotension, or hypertension within the past 2 years;
  8. History of any clinically significant disease, or any disease or condition that, in the opinion of the investigator, could affect the study results, including but not limited to circulatory, respiratory, endocrine, nervous, digestive, or urinary system, hematological, immunological, psychiatric, and metabolic diseases;
  9. History of organic heart disease, cardiac failure, myocardial infarction, angina pectoris, unexplained arrhythmia, Torsades de Pointes, ventricular tachycardia, atrioventricular block, long QT syndrome, or symptoms and family history of long QT syndrome (indicated by genetic proof or sudden cardiac death of a close relative at a young age);
  10. History of dysphagia, oesophageal stenosis, or gastrointestinal diseases causing clinically significant symptoms such as nausea, vomiting, diarrhoea, or malabsorption syndrome, or a history of severe vomiting or diarrhoea within one week prior to screening;
  11. History of surgery that, in the investigator's judgment, would affect drug absorption, distribution, metabolism, or excretion (e.g., gastrectomy, cholecystectomy, gastric bypass, duodenotomy, colectomy), or have undergone major surgery within 6 months prior to screening or whose surgical incision has not fully healed; major surgery includes, but is not limited to, any surgery with a significant risk of haemorrhage, a prolonged period of general anaesthesia, or incisional or significant traumatic injury, or planning to undergo surgery during the study;
  12. History of any known allergy to drugs, food, or environmental factors, especially allergy to components similar to the investigational product, or having an allergic constitution;
  13. Have symptomatic haemorrhoids or perianal diseases accompanied by regular/active haematochezia, irritable bowel syndrome, or inflammatory bowel disease;
  14. History of abnormal urination due to congenital or acquired urinary tract stenosis caused by infection/tumor, or bladder dysfunction;
  15. Clinically significant major infection within 2 months prior to screening (e.g., requiring hospitalization or parenteral antibacterial therapy), or active systemic bacterial, viral, or fungal infection, or clinically significant pyrexia, or unresolved infection within 2 weeks prior to screening, or a history of herpes zoster within 3 months prior to screening;
  16. Known or suspected history of immunodeficiency (e.g., history of frequent recurrent infections), history of hereditary or acquired complement deficiency;

    Lifestyle Habits:

  17. Habitual diarrhoea or average bowel movement frequency of less than once per day;
  18. Alcohol breath test result > 0 mg/100 mL or alcohol abuse within 3 months prior to screening, i.e., weekly alcohol consumption exceeding 14 units (1 standard unit equals 17.5 mL or 14 g pure alcohol; alcohol content for different types of alcoholic beverages is indicated by volume percentage; 1 standard unit is approximately equivalent to 35 mL of 50° liquor or 350 mL of 5° beer), or unwillingness to stop consuming alcohol or any alcohol-containing products during the study period;
  19. Use of tobacco products, nicotine, or nicotine-containing products (e.g., e-cigarettes) within 1 month prior to screening, or unwillingness to stop smoking during the study period;
  20. History of drug abuse or drug addiction, or a positive urine drug abuse screen;
  21. Excessive consumption (more than 8 cups per day, 1 cup = 250 mL) of tea, coffee, or caffeinated beverages daily within 3 months prior to screening; or intake of any foods or beverages containing or metabolized to produce caffeine or xanthine (e.g., coffee, tea, chocolate, cola, etc.) within 24 hours prior to admission;
  22. Have special dietary requirements or are unable to comply with the standardized diet (e.g., intolerance to standard meals); or refusal to abstain from foods or beverages that may affect the metabolism of the investigational product (e.g., foods or beverages containing grapefruit, carambola, or their products, etc.) from 48 hours before dosing until the end of the study;
  23. Plan to engage in strenuous exercise during the study;

    Others:

  24. Occupation involving long-term exposure to radioactive conditions; or significant radioactive exposure (e.g., ≥2 chest/abdominal CT scans, or ≥3 other types of X-ray examinations) within 1 year prior to screening, or participation in a radiolabeled drug trial within 1 year prior to screening;
  25. Have had blood loss or blood donation of >400 mL within 3 months prior to screening, or have had blood loss or blood donation of >200 mL within 1 month prior to dosing, or have received a transfusion of blood or blood components within 1 month, or plan to donate blood during the study drug administration period or within 3 months after discontinuation of the study drug;
  26. History of needle phobia or hemophobia, or difficulty with blood collection or inability to tolerate venipuncture blood collection;
  27. Have participated in any clinical trial and received an investigational drug or used an investigational device within 3 months prior to screening; or plan to participate in other clinical trials during this study, or not attending the clinical trial in person;
  28. Have received any vaccination within 4 weeks prior to screening or plan to receive any vaccination during the study or within 1 month after the end of the study;
  29. Have other factors deemed by the investigator to make the participant unsuitable for participation in this study, or participants who withdraw from the study for personal reasons.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 1
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    healthy postmenopausal female participants

    Drug: [14C]GS1-144

Interventions

  • 30 mg/100 µCi \[14C\]GS1-144, taken orally once

06

What researchers measure

Primary outcomes

  1. TRA recovery rate and cumulative TRA recovery rate for each time interval in excreta (urine and feces);

    Time frame: From the first administration until 240 hours later

  2. Percentage of parent drug and its metabolites in human plasma relative to TRA exposure (%AUC);

    Time frame: From the first administration until 240 hours later

  3. Percentage of parent drug and its metabolites in human urine and feces relative to the administered dose (%Dose); Identification of major metabolites in human plasma, urine, and feces;

    Time frame: From the first administration until 240 hours later

  4. PK parameters of TRA in human plasma and whole blood: Cmax

    Time frame: From the first administration until 168 hours later

  5. PK parameters of TRA in human plasma and whole blood: Tmax

    Time frame: From the first administration until 168 hours later

  6. PK parameters of TRA in human plasma and whole blood: t1/2

    Time frame: From the first administration until 168 hours later

  7. PK parameters of TRA in human plasma and whole blood: MRT

    Time frame: From the first administration until 168 hours later

  8. PK parameters of TRA in human plasma and whole blood: AUC0-t

    Time frame: From the first administration until 168 hours later

  9. PK parameters of TRA in human plasma and whole blood: AUC0-∞

    Time frame: From the first administration until 168 hours later

  10. PK parameters of TRA in human plasma and whole blood:λz

    Time frame: From the first administration until 168 hours later

  11. PK parameters of TRA in human plasma and whole blood: CL/F

    Time frame: From the first administration until 168 hours later

  12. PK parameters of TRA in human plasma and whole blood: Vz/F

    Time frame: From the first administration until 168 hours later

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2026 to primary completion in Apr 2026, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
Apr 17, 2026
StartActual
Apr 9, 2026
Primary completionActual
Apr 18, 2026
CompletionEst.
Dec 31, 2026
Last update
May 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07537231
Responsible party
Sponsor
First posted
Apr 17, 2026
Start date
Apr 9, 2026
Primary completion
Apr 18, 2026
Completion
Dec 31, 2026 (estimated)
Last update
May 7, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GS1-144

Start the discussion